PensionDanmark Pensionsforsikringsaktieselskab Acquires 38,596 Shares of Bristol Myers Squibb Company $BMY

PensionDanmark Pensionsforsikringsaktieselskab lifted its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 7.6% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 545,224 shares of the biopharmaceutical company’s stock after acquiring an additional 38,596 shares during the period. PensionDanmark Pensionsforsikringsaktieselskab’s holdings in Bristol Myers Squibb were worth $31,416,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in BMY. Darwin Wealth Management LLC acquired a new stake in shares of Bristol Myers Squibb in the 2nd quarter worth about $25,000. Swiss RE Ltd. bought a new stake in Bristol Myers Squibb in the 4th quarter valued at about $25,000. Physician Wealth Advisors Inc. raised its holdings in Bristol Myers Squibb by 73.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 202 shares during the period. Bayban purchased a new stake in shares of Bristol Myers Squibb during the fourth quarter worth $31,000. Finally, EQ Wealth Advisors LLC bought a new position in shares of Bristol Myers Squibb in the fourth quarter worth $32,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol Myers Squibb Stock Up 0.9%

Shares of NYSE:BMY opened at $64.19 on Friday. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. The firm has a market capitalization of $131.13 billion, a PE ratio of 14.14, a price-to-earnings-growth ratio of 0.16 and a beta of 0.22. The firm has a fifty day moving average of $58.56 and a 200 day moving average of $58.60. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $68.10.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. The company had revenue of $12.97 billion for the quarter, compared to analysts’ expectations of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.Bristol Myers Squibb’s revenue for the quarter was up 5.7% compared to the same quarter last year. During the same period last year, the firm posted $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, research analysts anticipate that Bristol Myers Squibb Company will post 6.97 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were paid a dividend of $0.63 per share. The ex-dividend date of this dividend was Thursday, July 2nd. This represents a $2.52 annualized dividend and a dividend yield of 3.9%. Bristol Myers Squibb’s dividend payout ratio (DPR) is 55.51%.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Analyst upgrades strengthen the outlook. Zacks upgraded BMY to Rank #2 (Buy), citing growing optimism about the company’s earnings prospects. Argus also raised its rating from “Hold” to “Buy” and set a $75 price target, implying further upside from recent levels. Bristol Myers Moves to Buy: Rationale Behind the Upgrade
• Positive Sentiment: Bristol Myers expanded its AI drug-discovery partnership with Schrödinger. Wider deployment of Schrödinger’s Bunsen and RetroSynth platforms across BMY’s research teams could improve drug-design efficiency and support the company’s longer-term pipeline, though the financial impact is not immediate. Schrödinger and BMS expand partnership
• Neutral Sentiment: Recent earnings momentum remains supportive. BMY previously reported earnings and revenue above analyst expectations, with revenue up year over year and full-year 2026 EPS guidance of $6.75-$7.00. This helps explain the stock’s strength and elevated investor interest.
• Neutral Sentiment: Alzheimer’s market developments offer limited direct benefit. The article highlights Leqembi and other disease-modifying therapies, but it does not identify a direct Bristol Myers product catalyst. Alzheimer’s Disease Market Pipeline Therapies
• Negative Sentiment: Merger speculation with AstraZeneca was denied. A senior source told Reuters there are “no discussions” regarding a potential transaction. That removes a possible takeover premium or strategic catalyst, although it also reduces uncertainty surrounding a major deal. No discussions over AstraZeneca-Bristol Myers deal

Analyst Ratings Changes

Several equities analysts have recently weighed in on BMY shares. Truist Financial reiterated a “buy” rating and issued a $70.00 price target (up from $65.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. BMO Capital Markets restated a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, July 27th. TD Cowen began coverage on Bristol Myers Squibb in a report on Wednesday. They set a “buy” rating for the company. Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 27th. Finally, Weiss Ratings upgraded shares of Bristol Myers Squibb from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, July 30th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $66.06.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.